Abstract 333P
Background
The CAPSTONE-1 study established adebrelimab plus carboplatin and etoposide as first-line standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC) in China. However, the safety and efficacy of adebrelimab in the second- or later-line settings remain unknown. Here, we present the first evaluation of the safety and effectiveness of adebrelimab for the second- or later-line treatment of ES-SCLC in a real-world setting.
Methods
In this prospective, multicenter, observational study in China, patients with ES-SCLC who were scheduled to receive adebrelimab-based second- or later-line treatment at the discretion of investigator were included. The primary outcome was safety profile according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Secondary outcomes included objective response rate (ORR), disease control rate (DCR), duration of response, progression-free survival (PFS), and overall survival (OS).
Results
Between March 10, 2023 and April 11, 2024, 75 patients were included (median age, 59 years [range, 38–81], 52 [69.3%] males, 10 [13.3%] current smokers, 27 [36.0%] with brain metastases, 18 [24.0%] with liver metastases, 31 [41.3%] with pleural effusion, and 22 [29.3%] with prior immunotherapy). As of December 2, 2024, the median follow-up duration was 6.5 months (interquartile range, 4.7–10.0). The ORR was 41.3% (95% CI, 30.1–53.3) and the DCR was 66.7% (95% CI, 54.8–77.1). Median PFS was 4.8 months (95% CI, 3.8–5.4), with the 6-month PFS rate of 36.7% (95% CI, 25.8–47.7). Median PFS was 3.9 months (95% CI, 2.1–6.9) in patients with prior immunotherapy and 5.1 months (95% CI, 3.9–6.1) in those without prior immunotherapy, without statistical difference (P=0.80). Median OS was 11.0 months (95% CI, 8.8-not reached). Treatment-emergent adverse events (TEAEs) of any grade were reported in 63 (84.0%) patients, and grade 3 or worse TEAEs occurred in 24 (32.0%) patients.
Conclusions
This study showed a manageable safety profile and favorable real-world effectiveness of adebrelimab-based therapy in the second- or later-line treatment of ES-SCLC.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.